Recent Investment Analysts’ Ratings Changes for West Pharmaceutical Services (WST)

Several brokerages have updated their recommendations and price targets on shares of West Pharmaceutical Services (NYSE: WST) in the last few weeks:

• 4/27/2026 – West Pharmaceutical Services was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 4/27/2026 – West Pharmaceutical Services was given a new $315.00 price target by Morgan Stanley.
• 4/27/2026 – West Pharmaceutical Services had its price target raised by Barclays PLC from $275.00 to $310.00. They now have an “equal weight” rating on the stock.
• 4/24/2026 – West Pharmaceutical Services had its “buy” rating reaffirmed by Citigroup Inc..
• 4/24/2026 – West Pharmaceutical Services had its “outperform” rating reaffirmed by Evercore Inc.
• 4/14/2026 – West Pharmaceutical Services was downgraded by Zacks Research from “strong-buy” to “hold”.
• 4/14/2026 – West Pharmaceutical Services had its price target raised by Barclays PLC from $265.00 to $275.00. They now have an “equal weight” rating on the stock.

West Pharmaceutical Services Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 6th. Shareholders of record on Wednesday, April 29th will be issued a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Wednesday, April 29th. West Pharmaceutical Services’s dividend payout ratio (DPR) is currently 11.76%.

Insider Buying and Selling at West Pharmaceutical Services

In other news, CAO Chad Winters sold 896 shares of the business’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $300.67, for a total value of $269,400.32. Following the completion of the sale, the chief accounting officer owned 1,523 shares of the company’s stock, valued at approximately $457,920.41. The trade was a 37.04% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Annette F. Favorite sold 2,817 shares of the company’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $305.20, for a total transaction of $859,748.40. Following the completion of the sale, the vice president owned 16,828 shares in the company, valued at approximately $5,135,905.60. This trade represents a 14.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.60% of the stock is owned by company insiders.

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.